PHARMARON

Pharmaron boosts its CDMO outlook, driving 10% profit growth and a 6.8% margin, as demand for contract drug development surges in a rebounding healthcare market.

Pharmaron Beijing thrives as China’s pharma sector rebounds—leveraging booming CRO demand, strong earnings from WuXi AppTec, and defensive ETF inflows to boost future growth potential.

Pharmaron, a key player in the Life Sciences Tools & Services industry, has reported a 20.64% increase in revenue and a 101.92% surge in net profit, positioning the company for continued growth in the innovative drug sector.